Optimal Treatment of Advanced Pancreatic Neuroendocrine Tumor.
10.15279/kpba.2016.21.3.128
- Author:
Yeon Suk KIM
1
;
Jae Hee CHO
Author Information
1. Department of Internal Medicine, Gachon University Gil Medical Center, Incheon, Korea. jhcho9328@gmail.com
- Publication Type:Review
- Keywords:
Pancreas neuroendocrine tumor;
Treatment;
Prognosis
- MeSH:
Drug Therapy;
Everolimus;
Humans;
Korea;
Neuroectodermal Tumors, Primitive;
Neuroendocrine Tumors*;
Prognosis;
Receptors, Peptide;
Somatostatin
- From:Korean Journal of Pancreas and Biliary Tract
2016;21(3):128-137
- CountryRepublic of Korea
- Language:Korean
-
Abstract:
Pancreatic neuroendocrine tumors (pNETs) are diverse diseases with different prognosis. Among available various therapeutic options, curative resection should be considered for localized tumors and in some selected cases of metastatic disease. Somatostatin analogs are used to control hormonal symptoms and also effective to inhibit the tumor progression in specific settings. The molecular targeted agents such as sunitinib and everolimus are efficacious treatments for metastatic WHO grade 1/2 pNETs. Chemotherapy is generally used in highly symptomatic and rapidly growing pNETs such as WHO grade 3. In addition, local ablative therapy should be considered in patients with hepatic predominant unresectable metastatic pNETs, and peptide receptor radionucleotide therapy, which is unavailable in Korea, could be considered after failure of initial medical therapy. The most important of all is a multidisciplinary approach to pNETs. This is essential to optimal management of pNETs regarding the diverse disease nature
